This article is part of the supplement: Current trends in leukemia, lymphoma, myeloma and ITP: updates and highlights from ASH 2008
Meeting abstract
Molecular target therapy – towards curative regimen: a 20-year experience in the treatment of acute promyelocytic leukemia (APL) in the Shanghai Institute of Hematology
-
Correspondence: Zhi-Xiang Shen drshenzx@yahoo.com
Shanghai Institute of Hematology, Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University of Medicine, Shanghai, PR China
Journal of Hematology & Oncology 2009, 2(Suppl 1):A1 doi:10.1186/1756-8722-2-S1-A1
Published: 26 June 2009First paragraph (this article has no abstract)
Since the first description of acute promyelocytic leukemia (APL) in 1957 as the most malignant form of acute leukemia, several developments have paved the way to make this disease the most curable leukemia in adults and change the paradigm of cancer treatment. Therapy of APL was pioneered by Bernard et al in 1973 demonstrating a striking sensitivity to daunorubicin, probably related to significantly lower P-glycoprotein expression observed in APL cells compared to other subtypes of acute myeloid leukemia (AML).